Randomized trial · people

Tirzepatide plus apitegromab: 1.9 kg less lean mass loss in EMBRAZE

Checked against the paper Randomized trialPublished by PepVault

The takeaway

Lean mass is lost along with fat during tirzepatide weight loss, and this early trial found an experimental add-on antibody reduced that lean mass loss without changing total weight loss.

Kind
Randomized trial
Studied in
People
Number studied
102
Published
2026
Journal
Nat Med

What they tested

The team tested whether adding apitegromab, an experimental antibody that blocks myostatin activation, to tirzepatide would limit the lean mass people lose as they lose weight.

How the study was done

A randomized, double-blind, placebo-controlled phase 2 trial in 102 adults with overweight or obesity. Everyone took tirzepatide, and they were split evenly to add either apitegromab (10 mg kg-1) or a placebo, a dummy treatment, for 24 weeks.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

Model. Individual results vary.

PepVault for iPhone

Taking tirzepatide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

At week 24, the apitegromab group lost 1.9 kg less lean mass than the placebo group (80% CI 1.2-2.7, P = 0.001). Total body weight loss was similar between the groups. The team described this as 54.9% retention of lean mass compared with placebo. Side effects were about as common in both groups: 39 of 51 (76%) on apitegromab and 36 of 51 (71%) on placebo, and serious side effects occurred in 1 of 51 people in each group.

What it doesn’t show

This was a small, 24-week phase 2 trial meant as an early test of the idea. The results are about lean mass, so effects on strength, physical function or longer-term health aren't shown.

The paper

Pratley et al. Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial. Nat Med. 2026.

The compound

More studies on Tirzepatide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking tirzepatide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo